Skip to main content
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

Table 6 Comparison of laboratory parameters and cognitive scale scores between MS patients distributed according to treatment type

From: Clinical predictors to cognitive impairment in multiple sclerosis patients

 

Treatment type

 
 

Immuno-modulator

Immunosuppressive

P value

ACE attention

 Mean ± SD

17.0 ± 1.2

15.9 ± 1.3

0.009*

ACE memory

 Mean ± SD

20.9 ± 2.2

18.1 ± 1.3

< 0.001*

ACE language

 Mean ± SD

23.3 ± 1.7

20.0 ± 1.6

< 0.001*

ACE fluency

 Mean ± SD

10.3 ± 1.6

9.9 ± 1.9

0.521

ACE visuospatial

 Mean ± SD

15.4 ± 1.1

15.3 ± 1.2

0.727

ACE total

 Mean ± SD

86.8 ± 5.7

79.3 ± 2.0

< 0.001*

PASAT 3

 Mean ± SD

23.6 ± 8.6

16.4 ± 7.7

0.011*

Trail making type B

 Mean ± SD

176.4 ± 67.1

212.9 ± 79.0

0.127

  1. *Statistically significant
  2. ACE Addenbrooke’s cognitive examination III, PASAT 3 Paced auditory serial addition test, SD standard deviation
  3. P value is significant if ≤ 0.050
Back to article page